BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12871078)

  • 1. Anti-epidermal growth factor receptor strategies to enhance radiation action.
    Lammering G
    Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):327-33. PubMed ID: 12871078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
    Harari PM; Huang SM
    Semin Radiat Oncol; 2001 Oct; 11(4):281-9. PubMed ID: 11677653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor tyrosine kinase inhibitors.
    Wakeling AE
    Curr Opin Pharmacol; 2002 Aug; 2(4):382-7. PubMed ID: 12127870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.
    Frederick B; Gustafson D; Bianco C; Ciardiello F; Dimery I; Raben D
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):33-7. PubMed ID: 16377413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development.
    Harari PM; Huang SM
    Semin Radiat Oncol; 2002 Jul; 12(3 Suppl 2):21-6. PubMed ID: 12174341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings.
    Milas L; Mason KA; Ang KK
    Int J Radiat Biol; 2003 Jul; 79(7):539-45. PubMed ID: 14530163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
    Grünwald V; Hidalgo M
    J Natl Cancer Inst; 2003 Jun; 95(12):851-67. PubMed ID: 12813169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
    Gainet M; Guardiola E; Dufresne A; Pivot X
    Cancer Radiother; 2003 Jun; 7(3):195-9. PubMed ID: 12834777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.
    Huang S; Peter Rodemann H; Harari PM
    Recent Results Cancer Res; 2016; 198():45-87. PubMed ID: 27318681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on epidermal growth factor receptor inhibitors.
    Modi S; Seidman AD
    Curr Oncol Rep; 2002 Jan; 4(1):47-55. PubMed ID: 11734113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.
    Fry DW
    Pharmacol Ther; 1999; 82(2-3):207-18. PubMed ID: 10454198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma.
    Waxman ES; Herbst RS
    Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):20-9. PubMed ID: 12053861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.
    Ghosh S; Liu XP; Zheng Y; Uckun FM
    Curr Cancer Drug Targets; 2001 Aug; 1(2):129-40. PubMed ID: 12188886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ErbB-targeted therapeutic approaches in human cancer.
    Arteaga CL
    Exp Cell Res; 2003 Mar; 284(1):122-30. PubMed ID: 12648471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
    Bellmunt J; Hussain M; Dinney CP
    Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S85-104. PubMed ID: 12850530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epidermal growth factor receptor and radiotherapy].
    Sirák I; Hatlová J; Petera J; Vosmik M; Ryska A; Vosmiková H
    Klin Onkol; 2008; 21(6):338-47. PubMed ID: 19382597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.